Sansure Biotech (SHSE:688289) Payments of Debt: ¥-101 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688289 Sansure Biotech Inc SHSE:688289
69 GF Score
Price ¥15.53
GF Value ¥22.32
Valuation Significantly Undervalued
! 7 Warning Signs
View Full Analysis

What is Sansure Biotech Payments of Debt?

Sansure Biotech SHSE:688289 -0.83% 69 Payments of Debt is ¥-101 Mil as of Jun. 2026. GuruFocus rates SHSE:688289 with a GF Score™ of 69/100 and a GF Value™ of ¥22.32 (Significantly Undervalued). The stock has 7 warning signs investors should review.

Sansure Biotech's Payments of Debt for the three months ended in Jun. 2026 was ¥-64 Mil.

Sansure Biotech's Payments of Debt for the trailing twelve months (TTM) ended in Jun. 2026 was ¥-101 Mil.

Sansure Biotech Payments of Debt Related Terms

Sansure Biotech Payments of Debt Historical Data

* Premium members only.

The historical data trend for Sansure Biotech's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sansure Biotech Payments of Debt Chart

Sansure Biotech Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only -55.00 0.00 -8.00 -9.00 -403.13

Sansure Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -24.40 15.40 -28.40 -64.02
SHSE:688289
69GF Score
Sansure Biotech Inc SHSE:688289
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sansure Biotech Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-101 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of ¥-101 Mil mean?
Sansure Biotech (SHSE:688289) has a Payments of Debt of ¥-101 Mil as of Jun. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Sansure Biotech and its competitors.
Is Sansure Biotech's Payments of Debt too high?
Sansure Biotech's current Payments of Debt is ¥-101 Mil. Overall, Sansure Biotech has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sansure Biotech's Payments of Debt compare to ISRG and BDX?
Sansure Biotech's Payments of Debt of ¥-101 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Medical Devices & Instruments company?
A good Payments of Debt depends on the Medical Devices & Instruments industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Sansure Biotech and its competitors. Sansure Biotech's current Payments of Debt is ¥-101 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sansure Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sansure Biotech (SHSE:688289) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥22.32, compared to a current price of ¥15.53 — trading 30.4% below its estimated fair value. The current Payments of Debt is ¥-101 Mil. Sansure Biotech's overall GF Score™ is 69/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Sansure Biotech (SHSE:688289), the current Payments of Debt is ¥-101 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sansure Biotech (SHSE:688289) Overvalued in 2026?

Based on GuruFocus' analysis, Sansure Biotech stock appears to be undervalued. The current stock price of ¥15.53 is trading 30.4% below its estimated GF Value™ of ¥22.32. GuruFocus considers Sansure Biotech to be Significantly Undervalued.

Key valuation signals for SHSE:688289:

  • Payments of Debt: ¥-101 Mil
  • GF Value™: ¥22.32 vs. price of ¥15.53 (30.4% below fair value)
  • GF Score™: 69/100 with 7 warning signs

No single metric tells the full story. See the SHSE:688289 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sansure Biotech Business Description

Address No. 680, Lusong Road, Changsha High-tech Industrial Development Zone, Hunan Province, Changsha, CHN, 410205
Sansure Biotech Inc is engaged in the Research, development, production, and sales of diagnostic reagents and instruments.
69GF Score

Get the complete analysis for SHSE:688289

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥15.53
Price
¥22.32
GF Value